OBJECTIVE: The disease process in rheumatoid arthritis (RA) starts years before the clinical diagnosis is made, and elevated levels of disease-specific autoantibodies can be detected during this period. Early responses to known or novel autoantigens likely drive the eventual production of pathogenic autoimmunity. Importantly, the presence of disease-specific autoantibodies can identify individuals who are at high risk of developing RA but who do not currently have arthritis. The goal of the current study was to characterize plasmablasts from individuals at risk of developing RA. METHODS: We investigated antibody-secreting plasmablasts derived from a well-characterized cohort of individuals who were at risk of developing RA, based on RA-related serum autoantibody positivity, as compared to patients with early (<1 year) seropositive RA as well as healthy control subjects. The plasmablast antibody repertoires of at-risk subjects were analyzed using DNA barcode-based methods with paired heavy- and light-chain gene sequencing. Cells were single-cell sorted, the cell- and plate-specific DNA barcodes were sequentially added, and next-generation sequencing was performed. RESULTS: Total plasmablast levels were similar in the antibody-positive (1%) and control (0.4-1.6%) groups. However, increased frequencies of IgA+ versus IgG+ plasmablasts were observed in the antibody-positive group (39% IgA+ and 37% IgG+) as compared to other groups (1-9% IgA+ and 71-87% IgG+). Paired antibody sequences from antibody-positive subjects revealed cross-isotype clonal families and similar sequence characteristics in the IgA and IgG plasmablast repertoires. Antibody-positive individuals also demonstrated elevated serum levels of IgA isotype anti-cyclic citrullinated peptide 3 antibodies. CONCLUSION: The IgA plasmablast dominance in these antibody-positive individuals suggests that a subset of RA-related autoantibodies may arise from mucosal immune responses and may be involved in early disease pathogenesis in individuals who are at risk of developing RA.
OBJECTIVE: The disease process in rheumatoid arthritis (RA) starts years before the clinical diagnosis is made, and elevated levels of disease-specific autoantibodies can be detected during this period. Early responses to known or novel autoantigens likely drive the eventual production of pathogenic autoimmunity. Importantly, the presence of disease-specific autoantibodies can identify individuals who are at high risk of developing RA but who do not currently have arthritis. The goal of the current study was to characterize plasmablasts from individuals at risk of developing RA. METHODS: We investigated antibody-secreting plasmablasts derived from a well-characterized cohort of individuals who were at risk of developing RA, based on RA-related serum autoantibody positivity, as compared to patients with early (<1 year) seropositive RA as well as healthy control subjects. The plasmablast antibody repertoires of at-risk subjects were analyzed using DNA barcode-based methods with paired heavy- and light-chain gene sequencing. Cells were single-cell sorted, the cell- and plate-specific DNA barcodes were sequentially added, and next-generation sequencing was performed. RESULTS: Total plasmablast levels were similar in the antibody-positive (1%) and control (0.4-1.6%) groups. However, increased frequencies of IgA+ versus IgG+ plasmablasts were observed in the antibody-positive group (39% IgA+ and 37% IgG+) as compared to other groups (1-9% IgA+ and 71-87% IgG+). Paired antibody sequences from antibody-positive subjects revealed cross-isotype clonal families and similar sequence characteristics in the IgA and IgG plasmablast repertoires. Antibody-positive individuals also demonstrated elevated serum levels of IgA isotype anti-cyclic citrullinated peptide 3 antibodies. CONCLUSION: The IgA plasmablast dominance in these antibody-positive individuals suggests that a subset of RA-related autoantibodies may arise from mucosal immune responses and may be involved in early disease pathogenesis in individuals who are at risk of developing RA.
Authors: G P Harvey; T R Fitzsimmons; A A S S K Dhamarpatni; C Marchant; D R Haynes; P M Bartold Journal: J Periodontal Res Date: 2012-09-16 Impact factor: 4.419
Authors: Lotte A van de Stadt; Margret H M T de Koning; Rob J van de Stadt; Gertjan Wolbink; Ben A C Dijkmans; Dörte Hamann; Dirkjan van Schaardenburg Journal: Arthritis Rheum Date: 2011-11
Authors: Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers Journal: J Clin Invest Date: 2006-04 Impact factor: 14.808
Authors: A Jimmy Ytterberg; Vijay Joshua; Gudrun Reynisdottir; Nataliya K Tarasova; Dorothea Rutishauser; Elena Ossipova; Aase Haj Hensvold; Anders Eklund; C Magnus Sköld; Johan Grunewald; Vivianne Malmström; Per Johan Jakobsson; Johan Rönnelid; Leonid Padyukov; Roman A Zubarev; Lars Klareskog; Anca I Catrina Journal: Ann Rheum Dis Date: 2014-05-09 Impact factor: 19.103
Authors: Henrik E Mei; Taketoshi Yoshida; Wondossen Sime; Falk Hiepe; Kathi Thiele; Rudolf A Manz; Andreas Radbruch; Thomas Dörner Journal: Blood Date: 2008-11-05 Impact factor: 22.113
Authors: Peggy P Ho; Lowen Y Lee; Xiaoyan Zhao; Beren H Tomooka; Ricardo T Paniagua; Orr Sharpe; Maya J BenBarak; Piyanka E Chandra; Wolfgang Hueber; Lawrence Steinman; William H Robinson Journal: J Immunol Date: 2009-11-30 Impact factor: 5.422
Authors: Jussi Vaahtovuo; Eveliina Munukka; Mika Korkeamäki; Reijo Luukkainen; Paavo Toivanen Journal: J Rheumatol Date: 2008-06-01 Impact factor: 4.666
Authors: Lindsay B Kelmenson; Brandie D Wagner; Bryan K McNair; Ashley Frazer-Abel; M Kristen Demoruelle; Dylan T Bergstedt; Marie L Feser; Laura K Moss; Mark C Parish; Elizabeth A Mewshaw; Ted R Mikuls; Jess D Edison; V Michael Holers; Kevin D Deane Journal: Arthritis Rheumatol Date: 2019-12-26 Impact factor: 10.995
Authors: Lisa K Blum; Richard R L Cao; Andrew J Sweatt; Matthew Bill; Lauren J Lahey; Andrew C Hsi; Casey S Lee; Sarah Kongpachith; Chia-Hsin Ju; Rong Mao; Heidi H Wong; Mark R Nicolls; Roham T Zamanian; William H Robinson Journal: Eur J Immunol Date: 2018-02-22 Impact factor: 5.532
Authors: Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers Journal: Best Pract Res Clin Rheumatol Date: 2017-09-18 Impact factor: 4.098
Authors: Serra E Elliott; Sarah Kongpachith; Nithya Lingampalli; Julia Z Adamska; Bryan J Cannon; Lisa K Blum; Michelle S Bloom; Matthew Henkel; Mandy J McGeachy; Larry W Moreland; William H Robinson Journal: Clin Immunol Date: 2020-02-05 Impact factor: 3.969
Authors: Lisa E Wagar; Ameen Salahudeen; Christian M Constantz; Ben S Wendel; Michael M Lyons; Vamsee Mallajosyula; Lauren P Jatt; Julia Z Adamska; Lisa K Blum; Neha Gupta; Katherine J L Jackson; Fan Yang; Katharina Röltgen; Krishna M Roskin; Kelly M Blaine; Kara D Meister; Iram N Ahmad; Mario Cortese; Emery G Dora; Sean N Tucker; Anne I Sperling; Aarti Jain; D Huw Davies; Philip L Felgner; Gregory B Hammer; Peter S Kim; William H Robinson; Scott D Boyd; Calvin J Kuo; Mark M Davis Journal: Nat Med Date: 2021-01-11 Impact factor: 53.440
Authors: Sarah Kongpachith; Nithya Lingampalli; Chia-Hsin Ju; Lisa K Blum; Daniel R Lu; Serra E Elliott; Rong Mao; William H Robinson Journal: Arthritis Rheumatol Date: 2019-02-27 Impact factor: 10.995
Authors: Serra E Elliott; Sarah Kongpachith; Nithya Lingampalli; Julia Z Adamska; Bryan J Cannon; Rong Mao; Lisa K Blum; William H Robinson Journal: Arthritis Rheumatol Date: 2018-10-20 Impact factor: 10.995
Authors: Anne H Rowley; Susan C Baker; David Arrollo; Leah J Gruen; Tetyana Bodnar; Nancy Innocentini; Matthew Hackbart; Yazmin E Cruz-Pulido; Kristine M Wylie; Kwang-Youn A Kim; Stanford T Shulman Journal: J Infect Dis Date: 2020-06-16 Impact factor: 5.226